公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2012 | Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia | Kantarjian H.M.; Thomas X.G.; Dmoszynska A.; Wierzbowska A.; Mazur G.; Mayer J.; Gau J.-P.; WEN-CHIEN CHOU ; Buckstein R.; Cermak J.; Kuo C.-Y.; Oriol A.; Ravandi F.; Faderl S.; Delaunay J.; Lys?k D.; Minden M.; Arthur C. | Journal of Clinical Oncology | 942 | 857 | |
2017 | Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma | Raje N.S.; Moreau P.; Terpos E.; Benboubker L.; Grząśko N.; Holstein S.A.; Oriol A.; SHANG-YI HUANG ; Beksac M.; Kuliczkowski K.; Tai D.F.; Wooldridge J.E.; Conti I.; Kaiser C.J.; Nguyen T.S.; Cronier D.M.; Palumbo A. | British Journal of Haematology | 37 | 33 |